Skip to main content
NCBI home page
PLOS One logoLink to PLOS One
. 2016 May 26;11(5):e0154816. doi: 10.1371/journal.pone.0154816

Molecular Analysis of Rising Fluoroquinolone Resistance in Belgian Non-Invasive Streptococcus pneumoniae Isolates (1995-2014)

Pieter-Jan Ceyssens 1, Françoise Van Bambeke 2, Wesley Mattheus 1, Sophie Bertrand 1, Frédéric Fux 1, Eddie Van Bossuyt 1, Sabrina Damée 1, Henry-Jean Nyssen 3, Stéphane De Craeye 3, Jan Verhaegen 4; The Belgian Streptococcus pneumoniae Study Group, Paul M Tulkens 2, Raymond Vanhoof 1,*
Editor: Eliane Namie Miyaji5
PMCID: PMC4881901  PMID: 27227336

Abstract

We present the results of a longitudinal surveillance study (1995–2014) on fluoroquinolone resistance (FQ-R) among Belgian non-invasive Streptococcus pneumoniae isolates (n = 5,602). For many years, the switch to respiratory fluoroquinolones for the treatment of (a)typical pneumonia had no impact on FQ-R levels. However, since 2011 we observed a significant decrease in susceptibility towards ciprofloxacin, ofloxacin and levofloxacin with peaks of 9.0%, 6.6% and 3.1% resistant isolates, respectively. Resistance to moxifloxacin arised sporadically, and remained <1% throughout the entire study period. We observed classical topoisomerase mutations in gyrA (n = 25), parC (n = 46) and parE (n = 3) in varying combinations, arguing against clonal expansion of FQ-R. The impact of recombination with co-habiting commensal streptococci on FQ-R remains marginal (10.4%). Notably, we observed that a rare combination of DNA Gyrase mutations (GyrA_S81L/GyrB_P454S) suffices for high-level moxifloxacin resistance, contrasting current model. Interestingly, 85/422 pneumococcal strains display MICCIP values which were lowered by at least four dilutions by reserpine, pointing at involvement of efflux pumps in FQ-R. In contrast to susceptible strains, isolates resistant to ciprofloxacin significantly overexpressed the ABC pump PatAB in comparison to reference strain S. pneumoniae ATCC 49619, but this could only be linked to disruptive terminator mutations in a fraction of these. Conversely, no difference in expression of the Major Facilitator PmrA, unaffected by reserpine, was noted between susceptible and resistant S. pneumoniae strains. Finally, we observed that four isolates displayed intermediate to high-level ciprofloxacin resistance without any known molecular resistance mechanism. Focusing future molecular studies on these isolates, which are also commonly found in other studies, might greatly assist in the battle against rising pneumococcal drug resistance.

Introduction

Streptococcus pneumoniae is a major cause of community-acquired respiratory infections including otitis media and pneumonia, as well of serious invasive infections like septicaemia and meningitis [1]. Penicillins and macrolides were mainstay in the treatment of respiratory diseases for decades [2], but the worldwide spread of drug-resistant clones translated into increased usage of fluoroquinolones [3,4]. Fluoroquinolones are synthetic, broad-spectrum antibiotics targeting the DNA gyrase (GyrA/B) and topoisomerase IV (ParC/E) enzymes, which are critically involved in DNA supercoiling and chromosome segregation, respectively [5]. The early fluoroquinolones ciprofloxacin (CIP) and ofloxacin (OFL) target ParC and display poor potency against pneumococci, rapidly leading to emergence of resistance [6]. In the late 1990s, they were replaced by the so-called “respiratory fluoroquinolones levofloxacin (LVX; the active isomer of ofloxacin) and moxifloxacin (MXF) that acts on both enzymes [2]. In Belgium, this has been reflected by steadily declining sales of OFL and norfloxacin while, in contrast, the use of MXF has markedly increased since 2009 (Fig 1) and will probably further expand as its patent has recently expired. Since the global switch to LVX and MXF was established, the worldwide prevalence of fluoroquinolone resistance (FQ-R) in S. pneumoniae remained below 2% [7] Moreover, it seems unrelated to the serotype switches that were observed upon the introduction of 7- and 13-valent pneumococcal conjugate vaccination [8].

Fig 1. Surveillance of Fluoroquinolone resistance in Belgian non-invasive S. pneumoniae isolates.

Fig 1

Open in a new tab

A. Clinical laboratories participating in the survey. Participating Flemish and Walloon laboratories are indicated in red and green, respectively. B. Evolution of the total Belgian fluoroquinolone use over the last decade, expressed as yearly sold units of the five main fluoroquinolones (source: IMS dataview, data December 2015).

Genetic analyses showed that a first mechanism of FQ-R is through stepwise accumulation of spontaneous mutations in the quinolone resistance determining regions (QRDR) of gyrA and parC, and rarely gyrB and parE [9]. The effect of a given mutation depends on the genetic context and the type of fluoroquinolone used [10]. ParC mutations at positions 79 and 83 are most frequently found among pneumococci and are associated with CIP and LVX usage [11]. These first-step mutations lead to a dramatic increase in mutant prevention concentration of all fluoroquinolones [12], enabling prompt selection of secondary and tertiary QRDR mutations in GyrA (mainly positions 81 and 85) required for the FQ-R phenotype [3]. Unlike β-lactam and macrolide resistance mechanisms, QRDR mutations do not appear to be clonally spread and only a minor fraction (0.5–10%) stems from recombination with co-habiting commensal streptococci of the viridans group [13].

In recent years, the role of efflux in low-level S. pneumoniae FQ-R has become more and more appreciated. Beyond causing a moderate increase in MIC, increased efflux is indeed associated with rising mutational frequencies in the QRDRs [14]. Gene disruption experiments, expression analyses and susceptibility testing in the presence of the efflux pump inhibitors led to current consensus that two distinct transporters, PmrA and PatA/B, are capable of fluoroquinolone efflux [15–19]. The Major Facilitator Superfamily pump PmrA, however, is reported as intrinsically inactive and non-inducible under CIP pressure [20]. More clinical relevance is therefore attributed to the reserpine-sensitive heterogenic ABC efflux pump PatAB. Deletion of this pump in a laboratory strain led to hypersusceptibility to CIP [21], and its expression is induced in the presence of CIP [20]. Moreover, constitutive overexpression of patA/B was observed in roughly one-third of clinical isolates with low-level FQ-R [17], and is linked to gene duplication and disruptive mutations in the transcriptional attenuator upstream patA [22–24]. Recently, point mutations in PatA were associated with increased CIP resistance by putative enhanced substrate binding [25].

Although most S. pneumoniae surveillance studies focus on bacteraemia, recent work estimated that for every adult bacteraemic case there are three non-invasive infections [26]. In this paper, we present data on FQ-R in non-invasive pneumococci from a longitudinal surveillance program across Belgian clinical laboratories (1995–2014), spanning the world-wide transit era between the use of early (CIP, OFL) and newer (LVX, MXF) fluoroquinolones. We noted that resistance against the early drugs are markedly on the rise since 2011. By studying the molecular background to dissect the relative contribution of target site mutations versus drug efflux, we identified interesting pneumococcal isolates which confer FQ-R through yet uncharacterized mechanisms.

Materials and Methods

Bacterial strains

Non-invasive respiratory clinical isolates of S. pneumoniae were collected during winter seasons between 1995 and 2014 in 15 clinical laboratories throughout Belgium by members of The Belgian Streptococcus pneumoniae Study Group. The access to patient information was encrypted. All isolates were kept at −70°C in Brain Heart Infusion Broth (Difco) containing 10% (v/v) glycerol until transfer to the Scientific Institute of Public Health for susceptibility testing and downstream molecular analyses. The identification of each isolate made by the participating laboratories was confirmed using PCR targeting the autolysin encoding gene lytA [26], slide agglutination (Slidex pneumo Kit™, BioMérieux, Marcy-l'Étoile, France) and Optochin (Opto-F, bioMérieux) tests, all performed according to the manufacturer’s instructions. For selected strains, capsular sequence typing (CST) was performed by sequence analysis of the wzh gene using a dedicated web application (http://www.rivm.nl/mpf/spn/cst/)[27].

Antibiotic susceptibility testing

For each isolate, the minimal inhibitory concentration (MIC) was determined by broth microdilution as recommended by the US Clinical and Laboratory Standards Institute (CLSI; called National Committee for Clinical Laboratory Standards (NCCLS) at the onset of the study in 1997. The following fluoroquinolones were provided as laboratory standards with known potency by the manufacturers of the original products: levofloxacin and ofloxacin from Aventis Pharma (Mumbai, India), CIP and MXF from Bayer (Leverkusen, Germany). All antibiotics were tested for 16 serial twofold dilutions (0.001–32 μg/mL), with S. pneumoniae ATCC 49619 [28,29], S. pneumoniae TPN 881, Staphylococcus aureus NCTC 11561 and S. aureus ATCC 29123 being included as quality control organisms in each series (S1 Table). Interpretation of the results was based on the breakpoints set by the European Committee on Antimicrobial Susceptibility Testing (EUCAST; http://www.eucast.org/). To assess possible synergy between fluoroquinolones and efflux pump inhibitors, commercial E-tests of CIP and MXF (bioMérieux) were applied on MH Blood agar plates containing 0 and 20 μg/mL reserpine. This method was devised after observing that reserpine causes turbidity of broth, preventing a correct reading of the results of the microdilution assay.

Determination of FQ-R related sequences

The DNA sequences of the QRDRs in gyrA, gyrB, parC and parE genes, and of the regulatory regions and coding sequences of patA and patB were determined by PCR sequencing using the primers listed in S2 Table. All sequences were screened for SNPs in comparison to corresponding regions of FQ-sensitive clinical strains using Clustal Omega (http://www.ebi.ac.uk/Tools/msa/clustalo/); the stability of the patA transcriptional attenuator was assessed using the MFold web server (http://unafold.rna.albany.edu/?q=mfold).

Quantitative real-time PCR

All tested S. pneumoniae strains were grown overnight in duplicate at 35°C and 5% CO2 on Mueller-Hinton agar plates supplemented with 5% defibrinated sheep blood (Bio-Rad Laboratories, Hercules, CA, USA). Bacteria were collected using a sterile loop and suspended in 15 mL Todd-Hewitt Broth medium to an OD620 nm of 0.1–0.2. These samples were incubated at 35°C with occasional stirring to late mid-late exponential phase (OD620 ~0.5–0.6), at which point 4 mL of the culture was sampled and cells were harvested by centrifugation (8,000 x g for 10 min at 4°C). Cell pellets were rapidly frozen at −80°C until further processing.

Total RNA extraction was performed using the InviTrap® Spin Cell RNA Mini Kit (Stratec Biomedical, Birkenfeld, Germany) according to the manufacturer’s instructions and stored at -80°C. Next, the samples were treated two consecutive times with 2 units TURBO™ DNase (Thermo Fisher, Waltham, USA) for 30 min at 37°C, followed by inactivation of the enzyme. To confirm removal of genomic DNA, the pmrA gene of S. pneumoniae was amplified as described elsewhere [19], and RNA concentrations were determined using Qubit fluorescence (Thermo Fisher).

cDNA was synthesized from 150 ng total RNA using the SuperScript® III First-Strand Synthesis System for RT-PCR (Life Technologies) according to the manufacturer’s instructions and using random hexamer primers. Residual RNA was removed using RNase III for 30 minutes at 37°C. Finally, real-time PCR was performed in an iQ cycler (Bio-Rad) in 25 μL reaction mixtures containing 12.5 μL of iQ SYBR Green Supermix (2×), 400 nM of forward and reverse primers and 5 μL of cDNA in RNase/DNase-free water. Primers used for amplification of pmrA, patA and patB are listed (S2 Table), and conditions were used as previously described [19]. Differential gene expression was calculated from the two replicates, as described in Pfaffl et al. [30] and using rpoD and proC genes as references to normalize transcript levels, as specified by PrimerDesign (Southampton, UK).

Results

Strain collection

A total of 5,602 unduplicated clinical isolates of S. pneumoniae were included in this study. Isolates were obtained from both ambulatory and hospitalized patients presenting a non-invasive respiratory clinical picture. These strains were collected during the winter seasons in 16 surveys spanning the period 1995 and 2014 by 15 participating clinical laboratories, determinedly selected to obtain a representative sampling of the country (Fig 1). Overall, 47.6% (varying between 40.9% and 53.9%) of the isolates were collected in the Southern part of the country, 44.7% (varying between 39.3% and 49.1%) in the Northern part and 7.6% (varying between 4.7% and 10.1%) in the Brussels area.

Annual fluoroquinolone resistance rates (1995–2014)

Annual MIC frequency distributions are presented in Table 1. From the onset of our study in 1995, nearly all isolates were classified as non-susceptible to CIP (96.2–100%) and OFL (97.3–100%). Nonetheless, high-level CIP resistance significantly increased from 0% resistant strains in 1995 and 1.4% in 2009, to 9.0% in 2013 (P = 0.00025, χ2 trend analysis including Bonferroni’s correction) (Table 1). In the same time period, the MIC50 of OFL significantly increased from 1 to 2 μg/mL (P < 10−6; χ2 linear trend analysis, Extended Mantel-Haenszel method), leading to a peak in resistance (6.6%) in 2013. Regarding the respiratory fluoroquinolones, LVX resistance peaked to 3.3% in 2003 and 3.1% in 2012, but remained in general below 2%. Notably, the levofloxacin MIC50 also increased significantly from 0.5 to 1 μg/mL since 2012 (P < 10−6). MXF was the fluoroquinolone with the highest intrinsic activity on weight basis, with a stable MIC50 at 0.06 μg/mL (P = 0.64). Resistance to MXF arose only sporadically, and remained <1% throughout the entire study period (Table 1).

Table 1. Yearly percentage of isolates displaying indicated MIC (μg/mL) against four fluoroquinolones.

The MIC50 values are indicated with an asterisk. The breakpoints (separating the isolates according to their susceptibility to each drug) are those set by EUCAST.

CIPROFLOXACIN Susceptible Intermediate Resistant
Year # strains 0.015 0.03 0.06 0.12 0.25 0.5 1 2 4 8 16 32 % res.
1995 143 - - 0.7 2.8 18.9 34.3* 35.7 7.7 - - - - 0.0
1997 162 - - - - 6.8 17.9 61.7* 11.7 2.5 0.6 - - 3.1
1999 227 - - 0.4 0.4 6.2 30.8 47.1* 13.2 1.8 - - - 1.8
2001 334 - - - 0.9 12.9 38* 38 6.6 3 0.6 - - 3.6
2003 391 - - 0.5 3.1 11.3 25.1 46.3* 9.5 2.6 1.8 - - 4.4
2004 424 - 0.2 1.2 1.9 14.2 37.3* 36.3 6.6 2.1 - 0.2 - 2.3
2005 447 - 0.2 1.1 2.5 12.8 35.6* 40.5 6 0.9 0.2 0.2 - 1.3
2006 430 - - 0.2 1.4 7.4 28.6 53.7* 8.1 0.5 - - - 0.5
2007 413 - - 0.2 1.5 7.7 30 56.7* 1.7 1.5 0.2 0.5 - 2.2
2008 448 - - 0.2 0.4 4.7 16.1 73.4* 4.7 - - 0.4 - 0.4
2009 413 - - - 1.9 6.5 44.1* 44.1 1.9 1 0.2 0.2 - 1.4
2010 370 - - 0.8 2.7 10.8 26.2 55.1* 1.9 2.2 - - 0.3 2.5
2011 368 - - 0.3 0.5 4.6 14.9 46.2* 29.6 2.2 1.1 0.5 - 3.8
2012 351 - - - 0.3 1.1 14.2 46.4* 29.9 7.1 0.6 0.3 - 8.0
2013 369 - - - - 3 12.5 38.8* 36.9 7.3 1.1 0.3 0.3 9.0
2014 312 - - - - 0.6 9.9 49.7* 33 6.4 - 0.3 - 6.7
OFLOXACIN Susceptible Intermediate Resistant
Year # strains 0.03 0.06 0.12 0.25 0.5 1 2 4 8 16 32 64 % res.
1995 143 - - - 5.6 22.4 48.9* 15.4 7.7 - - - - 0.0
1997 162 - - - - 7.4 43.8* 32.1 15.4 1.2 - - - 1.2
1999 227 - - 0.4 0.8 10.6 45.8* 27.3 13.2 1.8 - - - 1.8
2001 334 - - - 2.1 11.4 46.1* 30.2 6.6 3.3 0.3 - - 3.6
2003 391 - - 0.5 2.8 13.6 40.4* 29.2 9.2 3.1 0.8 0.5 - 4.4
2004 424 - - 1.1 6.8 13 58* 12 6.6 2.1 0.2 - - 2.3
2005 447 - - 2.7 3.6 25.7 44.5* 16.1 6 1.1 0.2 - - 1.3
2006 430 - - 0.5 1.8 11.6 51.6* 26 7.9 0.5 - - - 0.5
2007 413 - 0.5 - 1.5 9.7 51.1* 33.7 1.7 1.3 0.7 - - 2.0
2008 448 - - 0.2 0.9 4 56* 33.7 4.7 - 0.4 - - 0.4
2009 413 - - - 1.9 9 46.7* 39 2.4 0.5 0.5 - - 1.0
2010 370 - - 1.1 3.5 9.2 48.9* 33 2.7 1.4 0.3 - - 1.7
2011 368 - 0.3 - 1.4 4.3 32.1 50.5* 9.2 1.6 0.5 - - 2.1
2012 351 - - - 0.9 2.3 32.8 51.6* 11.1 1.4 - - - 1.4
2013 369 - - - 0.3 4.6 31.7 48.5* 8.4 6 0.3 0.3 - 6.6
2014 312 - - - - 1 27.6 64.1* 4.5 2.6 - 0.3 - 2.9
LEVOFLOXACIN Susceptible Resistant
Year # strains 0.03 0.06 0.12 0.25 0.5 1 2 4 8 16 32 64 % res.
1995 143 - 1.4 2.8 19.6 40.6* 30.1 5.6 - - - - - 0.0
1997 162 - - 0.6 8 58.6* 26.5 4.9 1.2 - - - - 1.2
1999 227 - 0.4 - 2.6 37.9 44.1* 13.2 1.8 - - - - 1.8
2001 334 - - 1.2 9 47.6* 33.2 6.3 2.4 0.3 - - - 2.7
2003 391 - 0.5 3.6 13.6 31.7* 41.4 5.9 1.8 1.5 - - - 3.3
2004 424 0.5 0.7 3.8 14.2 42.7* 30.2 5.2 2.6 - 0.2 - - 2.7
2005 447 0.9 2 4.5 22.6 48.1* 15.9 5.4 0.4 - 0.2 - - 0.6
2006 430 0.2 1.2 2.1 9.3 28.6* 53.7 8.1 0.5 - - - - 0.5
2007 413 0.2 0.5 2.2 13.8 58.1* 23.5 0.7 0.2 0.7 - - - 0.9
2008 448 0.2 - 1.1 6.9 60.7* 26.1 4.2 0.2 - 0.4 - - 0.6
2009 413 - 1.2 5.3 30.8 46.2* 15 0.7 0.2 0.5 - - - 0.7
2010 370 0.3 3.5 4.3 17 55.9* 15.7 2.4 0.5 0.3 - - - 0.8
2011 368 0.3 0.5 3 10.1 37* 41.3 6.8 0.5 0.5 - - - 1.0
2012 351 - - 0.9 3.7 41.3 39* 12 2.8 0.3 - - - 3.1
2013 369 - - 1.4 2.7 35 49.3* 10.3 0.8 0.3 0.3 - - 1.4
2014 312 - - 0.6 2.2 30.8 59.6* 6.1 0.3 - 0.3 - - 0.6
MOXIFLOXACIN Susceptible Resistant
Year # strains 0.008 0.015 0.03 0.06 0.12 0.25 0.5 1 2 4 8 16 % res.
1995 143 - 9.1 33.6 38.5* 13.3 0.7 - - - - - - 0.0
1997 162 - 0.6 12.3 38.9* 44.4 3.1 0.6 - - - - - 0.0
1999 227 0.4 1.8 11 40.1* 30.4 12.8 2.6 0.9 - - - - 0.9
2001 334 0.6 6.3 9.3 43.7* 32.3 5.4 1.5 0.6 0.3 - - - 0.9
2003 391 1 6.6 13.6 30.2* 36.8 10.5 0.8 - 0.3 0.3 - - 0.6
2004 424 0.5 4.5 17 39.4* 30.2 8 0.2 - 0.2 - - - 0.2
2005 447 1.1 4 18.6 39.6* 28.2 6.9 1.3 - 0.2 - - - 0.2
2006 430 1.8 4.7 17 41.4* 30.9 - 0.2 - - - - - 0.0
2007 413 0.7 2.9 11.1 43.1* 30 11.4 - 0.5 0.2 - - - 0.7
2008 448 0.2 0.9 7.4 38.6* 46.4 6.9 - - 0.2 - 0.2 - 0.4
2009 413 0.2 5.3 11.1 51.3* 25.2 6.3 0.2 0.2 - - - - 0.2
2010 370 - 5.4 11.6 49.5* 26.8 5.7 0.8 - - 0.3 - - 0.3
2011 368 0.3 3.3 12.8 48.9* 27.2 6.5 0.5 0.5 - - - - 0.5
2012 351 - 2.3 5.4 48.1* 36.5 6.6 0.9 0.3 - - - - 0.3
2013 369 - 1.4 9.5 53.9* 30.1 4.3 - - 0.8 - - - 0.8
2014 312 - 0.3 8.3 52.6* 34.3 4.2 - - 0.3 - - - 0.3
Open in a new tab

Next, we investigated the influence of the role of efflux in fluoroquinolone resistance using the efflux pump inhibitor reserpine. Hereto, we selected 422 pneumococcal isolates displaying varying MICCIP and repeated the MIC testing of CIP and MXF in the presence of reserpine (MICCIP/MXF+R). We observed that for 85 (20.1%) isolates, at least a fourfold decrease in MICCIP was achieved upon addition of the efflux pump inhibitor (Fig 2), which is a common threshold for the definition of an efflux phenotype [31,32]. For 57 (13.5%) isolates there was no effect, while in 16 cases (3.7%) this reduction was very drastic and caused a decrease to up to nine MICCIP dilutions, accounting for the entire resistance phenotype. In contrast, MXF MICs were much less decreased by the addition of reserpine as the maximal effect was a two-fold reduction in 45 (10.7%) strains (Fig 2). Of note, we used E-tests for all analyses which included reserpine, and recorded MICs which were generally higher than with the corresponding microdilution method: 52.8% one or less, and 90.2% two or less dilutions difference in CIP MICs, and 56.7% one or less, and 89.2% two or less dilutions difference for MXF (S4 Table). Comparable deviations have been reported elsewhere for other Gram-positive bacteria [33–35], and could be attributed to a conservative interpretation due to insufficient growth of the bacterial lawn.

Fig 2. MIC distributions of ciprofloxacin and moxifloxacin (E-test method) for 422 non-invasive S. pneumoniae isolates collected in Belgium between 1995 and 2014.

Fig 2

Open in a new tab

Left-hand panels: MIC distributions determined in the absence (control; black) or presence (green) of 20 mg/L reserpine. Right-hand panels: reduction of MIC (in blocks of 0.5 log2 dilutions from 0 to 3 log2 dilutions) after addition of 20 mg/L reserpine and plotted as a function of the MIC distribution of the isolates in the absence of reserpine.

Analysis of QRDR regions and serotypes

For the same set of 422 isolates, the QRDR of all gyrA, gyrB, parC and parE genes were sequenced (Table 2 and S4 Table). To dissect the influence of QRDR from efflux-mediated resistance, various genotypes were grouped according to the MIC of CIP when tested in the presence of reserpine (MICCIP+R) for each strain. Firstly, this allowed identifying a magnitude of topoisomerase mutations unrelated to FQ-R, most prevalent being ParC K137N, K57T and ParE I460V [8–10] occurring in 14.7, 2.2 and 81.0% pneumococcal isolates with MICCIP+R <1 μg/mL, respectively. Secondly, we identified signatures of recombination with members of the S. mitis group, judged by the presence of ParC S52G, N91D and/or GyrA S114G substitutions [13], in 10.4% of the strains. These recombinant genes were already identified at the onset of our study, but no significant increase in topoisomerase recombination was noted by 2014.

Table 2. Overview of the various FQ-R genotypes encountered in 422 clinical S. pneumococci strains.

Signature residues of the viridans group of streptococci [13] are indicated in bold.

MICCIP+R (μg/ml) MICMXF+R (μg/ml) No. isolates GyrA GyrB ParC ParE
S81 E85 S114 P454 S52 N91 D78 S79 D83 D435
< 1 0.064–0.19 289 - - - - - - - - - -
(n = 311) 10 - - G - - - - - - -
6 - - G - G D - - - -
2 - - - - - D - - - -
2 - - - - G D - - - -
1 - - G - G - - - - -
1 F - - - - - - - - -
≤ 2 0.125–0.25* 47 - - - - - - - - - -
(n = 80) 12 - - - - - - - F - -
1 - - - - - - N - - -
1 F - - - - - - - - -
1 - - - - - D - F - -
2 - - - - - - - - N/Y -
1 - - - - - - - F - K
1 - - G - G D - F - -
5 - - G - - - - - - -
5 - - G - G D - - - -
4 - - G - - D - - - -
2–4 0.19–1 3 - - - - - - - - - -
(n = 12) 4 - - - - - - - Y/F - -
1 F - - - - - - - - N
1 - - - - - D - F - -
1 - - - - - - - - G -
1 - - G - - - - - - -
1 - - G - G D - - - -
1 - - - - - - - - - -
3 F - - - - - - - - -
≥4 1–32 1 F - - - - - - - - N
(n = 29) 12 F - - - - - - F/Y - -
2 F - - - - - - - G/Y -
2 - - G - - D - F - -
1 Y - G - - D - Y - -
1 G - - - - - - - - -
2 - - - - - - - - N -
2 - - - - - - - F/Y - -
1 - K - - - - - Y - -
1 L - G S - - - - - -
Open in a new tab

Only shown are amino acid substitutions involved in resistance and recombination with the viridans group. -, wild type. Identified mutations not involved in resistance were GyrA: M99I (n = 3), G112D (n = 2), G103S, L152R, L155F, L155V, L154F, L157F(n = 1); GyrB: G434R (n = 4), D435N, S466G, F480L (n = 1); ParC: K137N (n = 64), K57T (n = 11), R95C/G (n = 3), E134D, E135D (n = 1); ParE: I460V (n = 232), H534L/Q (n = 6), I493L (n = 3), A532T/V (n = 2), D435N, l431S, I493L, A468T, Y481H, K448P, Q420P (n = 1).

*0.38 for the isolate with S81F

Classical QRDR mutations were retrieved in GyrA at positions 81 (n = 24) and 85 (n = 1), ParC positions 78 (n = 1), 79 (n = 38) and 83 (n = 7), and ParE position 435 (n = 3). These topoisomerase mutations were found in varying combinations, arguing against clonal expansion of FQ-R (Table 2). To investigate this hypothesis, we performed CST typing on 54 FQ-R isolates which showed a wide variety of associated serotypes (S3 Table). In concordance to previous studies, isolates carrying mutations in both topoisomerases unequivocally displayed high-level resistance to CIP (MICCIP+R > 12 μg/mL). In contrast, strains with sole mutations in ParC (50.9% of isolates with mutated QRDR) or GyrA (13.7%) display more variable MICCIP+R values. For example, four strains carrying a GyrA S81F/G mutation displayed a MICCIP+R of 32 μg/mL (e.g., 13C28), whereas other strains with the same mutation (e.g., 05A05 and 04L17) only reached 0.5–1 μg/mL.

Finally, some interesting genotypes were observed. For example, we identified a very rare GyrB mutation (P454S) in isolate 05A20 which, in combination with GyrA S81L and wild-type Topoisomerase IV, was correlated with full resistance to MXF (MICMXF+R = 32 μg/mL) (Table 2). An even more noticeable result was that some isolates with complete wild-type QRDRs (e.g., 13C24, 11I08) were nevertheless fully resistant to CIP, even in the presence of reserpine (Table 2).

Efflux pump expression analysis

Next, we assessed the contribution of PmrA and PatAB efflux transporters to FQ-R by measuring early-log expression levels of patA, patB and pmrA in 94 S. pneumoniae isolates grown in the absence of antibiotics, in comparison to the control strain S. pneumoniae ATCC 49619 [27,28]. Strains were selected based on various susceptibilities to reserpine, i.e. displaying either no (n = 2), 1- (n = 8), 2- (n = 20), 3- (n = 24), 4-(n = 25) or ≥5 (n = 14) fold MICCIP reductions in the presence of this efflux pump inhibitor. The results are shown in Table 3.

Table 3. Expression analyses of a selection of S. pneumoniae strains, with inclusion of the QRDR sequences and phenotypic FQ-R analyses.

Strain Id. Topoisomerase mutations MICCIP + reserpine (μg/ml)a MICMXF + reserpine (μg/ml)a Gene expression
GyrA GyrB ParC ParE 0 20 0 20 pmrA patA patB
07A40 S81F wt S79F wt >32 >32 3 2 0.6 ± 0.2 11.2 ± 4.3 0.7 ± 0.2
10N11 S81F wt S79Y wt >32 >32 8 4 0.3 ± 0.1 10.4 ± 2.9 281.5 ± 37.7
12K23 wt wt wt I460V 1 0.75 0.125 0.094 1.7 ± 1.1 2.8 ± 1.8 19.9 ± 12.4
ATCC wt wt wt wt 0.5 0.35 0.064 0.064 1 1 1
99H18 wt wt wt I460V 1.5 1 0.19 0.125 13.1 ± 8.5 0.2 ± 0.1 10.2 ± 7.7
12M03 wt wt wt I460V 1.5 1 0.125 0.125 1.3 ± 0.4 1.3 ± 0.6 10.0 ± 3.5
08 E03 wt wt R95C wt 0.75 0.5 0.094 0.064 1.0 ± 0.2 1.9 ± 0.6 0.7 ± 0.3
05A07 wt S466G K57T I460V 0.75 0.38 0.125 0.094 0.2 ± 0.1 1.0 ± 0.2 10.3 ± 2.8
11I08 wt wt wt I460V 32 16 1 1 1.0 ± 0.3 0.5 ± 0.3 0.7 ± 0.1
11A23 wt wt D83N I460V >32 16 1.5 1.5 0.3 ± 0.1 3.3 ± 0.8 39.2 ± 10.7
08A02 wt wt wt wt 0.5 0.25 0.125 0.064 0.4 ± 0.06 1.1 ± 0.1 0.4 ± 0.1
09K10 wt wt wt I460V 1 0.5 0.094 0.094 3.8 ± 1.7 0.3 ± 0.1 0.3 ± 0.1
13L15 wt wt wt I460V 1.5 0.75 0.125 0.125 1.7 ± 0.8 1.8 ± 0.9 13.7 ± 7.0
11I10 wt wt wt I460V 1 0.5 0.125 0.125 0.8 ± 0.2 1.9 ± 0.6 16.9 ± 5.5
09K03 wt wt wt I460V 1 0.5 0.094 0.094 1.6 ± 0.4 0.2 ± 0.04 0.7 ± 0.2
97G03 wt wt S79F A532T 2 1 0.19 0.125 4.1 ± 1.3 0.1 ± 0.05 9.1 ± 3.3
11I29 wt wt wt I460V 1.5 0.75 0.125 0.125 0.9 ± 0.4 1.5 ± 0.8 24.4 ± 10.3
10A15 wt wt wt wt 1 0.5 0.125 0.125 1.1 ± 0.4 2.3 ± 0.7 68.0 ± 22.0
07M27 wt wt R95C wt 1 0.5 0.125 0.125 1.6 ± 0.9 4.1 ± 2.5 0.2 ± 0.1
09L20 wt wt wt I460V 1 0.5 0.125 0.094 6.7 ± 5.4 3.6 ± 3.1 2.1 ± 1.2
09N30 wt wt wt I460V 1.5 0.75 0.064 0.064 2.6 ± 0.9 9.1 ± 3.4 8.2 ± 2.8
04F27 wt wt wt I460V 1 0.38 0.094 0.064 1.9 ± 0.9 1.8 ± 0.3 11.8 ± 2.3
05C40 wt wt K137N I460V 1 0.38 0.125 0.094 5.3 ± 3.5 4.5 ± 2.3 25.4 ± 13.0
01H28 S81F wt K137N I460V 32 12 3 2 10.7 ± 4.1 1.6 ± 0.4 15.1 ± 3.3
13A22 wt wt wt I460V 4 1.5 0.125 0.125 0.5 ± 0.3 2.6 ± 1.5 14.8 ± 8.5
09K16 wt wt wt I460V 2 0.75 0.125 0.125 1.8 ± 1.1 0.3 ± 0.1 0.4 ± 0.5
11O31 S114G wt wt wt 4 1.5 0.125 0.125 5.7 ± 5.7 14.3 ± 12.6 24.3 ± 3.9
07O07 S114G wt S79F/N91D I460V 16 6 0.25 0.25 0.6 ± 0.03 1.8 ± 0.0 0.5 ± 0.1
97B14 L154F wt wt I460V 1.5 0.5 0.094 0.094 2.4 ± 0.8 0.08 ± 0.03 9.8 ± 4.1
04A10 wt wt wt I460V 1.5 0.5 0.125 0.125 9.3 ± 3.3 0.5 ± 0.2 0.3 ± 0.2
97I27 wt wt wt I460V 1.5 0.5 0.125 0.094 8.4 ± 3.7 0.1 ± 0.04 9.7 ± 4.2
04A25 wt wt wt I460V 3 1 0.19 0.19 9.4 ± 5.4 0.4 ± 0.2 0.4 ± 0.2
13L23 wt wt wt I460V 3 1 0.19 0.19 1.7 ± 0.5 14.8 ± 4.4 48.4 ± 10.5
06N06 wt wt wt I460V 1.5 0.5 0.125 0.125 1.1 ± 0.2 2.4 ± 0.6 0.2 ± 0.1
13B09 wt wt wt I460V 1.5 0.5 0.094 0.094 0.8 ± 0.5 1.0 ± 0.5 9.6 ± 6.1
95B18 wt wt wt wt 1.5 0.5 0.125 0.125 1.4 ± 0.5 42.4 ± 15.0 198.6 ± 71.1
4E+13 wt wt wt I460V 1.5 0.5 0.125 0.125 3.7 ± 1.5 0.5 ± 0.3 0.1 ± 0.1
95C17 wt wt wt I460V 0.75 0.25 0.094 0.094 2.0 ± 0.2 0.3 ± 0.1 2.8 ± 1.1
13E324 S114G wt wt I460V 1.5 0.5 0.125 0.125 0.8 ± 0.4 1.9 ± 0.9 9.2 ± 4.6
13L14 wt wt wt I460V 3 1 0.19 0.19 1.2 ± 0.5 2.5 ± 1.1 13.3 ± 5.7
04L07 wt wt wt I460V 1.5 0.5 0.094 0.094 3.9 ± 1.9 1.3 ± 0.6 0.5 ± 0.2
06A24 wt wt wt I460V 1.5 0.5 0.125 0.125 0.6 ± 0.2 2.4 ± 1.0 0.5 ± 0.2
10I25 wt wt wt I460V 3 1 0.125 0.125 1.2 ± 0.6 6.6 ± 2.2 72.2 ± 45.7
04C04 wt wt wt I460V 1.5 0.5 0.094 0.094 4.3 ± 1.8 2.8 ± 1.4 1.3 ± 0.5
95C08 wt wt S52G/N91D I460V 1.5 0.5 0.19 0.19 1.6 ± 1.4 6.2 ± 4.6 32.9 ± 24.2
04L24 wt wt K137N I460V 1.5 0.5 0.094 0.094 4.5 ± 0.8 1.8 ± 0.3 0.5 ± 0.1
10L18 wt wt wt I460V 1.5 0.5 0.25 0.25 1.1 ± 0.3 1.5 ± 0.5 16.1 ± 5.3
13A12 wt wt wt I460V 1.5 0.5 0.125 0.125 1.4 ± 0.4 3.5 ± 0.3 25.0 ± 3.0
09O15 wt wt wt I460V 0.75 0.25 0.064 0.064 1.2 ± 0.1 0.5 ± 0.07 0.4 ± 0.07
06O04 wt wt wt wt 1.5 0.38 0.094 0.094 0.7 ± 0.4 2.0 ± 1.1 0.3 ± 0.1
08J09 wt wt wt I460V 2 0.5 0.125 0.094 0.7 ± 0.08 0.15 ± 0.0 0.2 ± 0.1
13B01 wt wt wt I460V 3 0.75 0.19 0.19 0.9 ± 0.2 1.5 ± 0.3 8.6 ± 2.6
06A08 S114G wt wt A496T 2 0.5 0.094 0.125 3.6 ± 2.4 2.3 ± 1.4 12.2 ± 7.9
99H17 wt wt wt wt 0.5 0.125 0.064 0.032 7.7 ± 3.0 0.09 ± 0.04 8.9 ± 3.7
06J35 wt wt wt wt 2 0.5 0.125 0.125 1.4 ± 0.8 1.4 ± 0.7 11.0 ± 5.8
12M02 wt wt S79F/ N91D I460V 4 1 0.125 0.125 4.1± 0.6 0.03 ± 0.01 10.8 ± 1.8
95B16 S114G wt S52G/N91D wt 4 1 0.25 0.19 2.7 ± 0.8 0.04 ± 0.0 4.8 ± 1.1
99A09 wt wt wt I460V 2 0.5 0.19 0.125 11.0 ± 9.6 0.2 ± 0.1 9.3 ± 8.4
08G28 wt wt wt I460V 3 0.75 0.125 0.094 0.3 ± 0.03 0.4 ± 0.03 0.2 ± 0.0
06J37 wt wt wt I460V 2 0.5 0.125 0.125 1.4 ± 0.4 1.6 ± 0.9 5.8 ± 0.7
01H21 S81F wt K137N D435N 16 4 1.5 1 9.9 ± 3.3 3.0 ± 0.6 13.3 ± 4.5
03L14 wt wt wt I460V 2 0.5 0.094 0.094 4.4 ± 2.4 0.7 ± 0.4 0.3 ± 0.2
05A28 S114G wt S52G/N91D wt 4 1 0.19 0.19 0.02 ± 0.0 0.8 ± 0.3 0.7 ± 0.2
08G25 wt G434R wt I460V 2 0.5 0.125 0.094 0.2 ± 0.02 2.4 ± 0.4 0.6 ± 0.1
95F08 wt wt wt I460V 2 0.5 0.094 0.094 4.5 ± 2.7 2.0 ± 1.1 53.7 ± 28.7
07H01 wt wt S79F I460V 4 1 0.125 0.125 1.5 ± 0.9 21.4 ± 11.9 5.6 ± 3.0
08G26 wt wt wt I460V 2 0.5 0.094 0.094 1.1 ± 0.5 3.0 ± 1.5 0.4 ± 0.2
08O21 wt wt K137N I460V 2 0.5 0.125 0.125 1.9 ± 0.6 6.5 ± 1.3 1.6 ± 0.3
05D34 wt wt wt I460V 4 1 0.125 0.125 7.0 ± 0.4 0.3 ± 0.04 2.8 ± 0.1
10K19 wt wt wt I460V 6 1.5 0.125 0.125 0.5 ± 0.05 11.1 ± 1.1 208.7 ± 34.9
97A11 wt wt wt I460V 2 0.5 0.125 0.125 1.8 ± 0.6 1.0 ± 0.3 121.4 ± 49.5
97B21 wt wt wt wt 2 0.38 0.125 0.094 1.7 ± 0.8 0.2 ± 0.1 18.7 ± 10.3
05A34 S114G wt S52G/N91D wt 4 0.75 0.19 0.19 0.3 ± 0.1 0.3 ± 0.1 0.04 ± 0.01
99D02 wt wt K137N I460V 4 0.75 0.094 0.064 1.1 ± 0.4 0.4 ± 0.2 34.9 ± 12.1
99J08 wt wt wt I460V 4 0.75 0.125 0.125 3.2 ± 2.2 1.4 ± 1.1 134.0 ± 96.9
97B25 wt wt ND wt 24 4 0.38 0.38 2.2 ± 1.3 0.1 ± 0.08 10.0 ± 5.9
08 E15 wt wt wt I460V 6 1 0.125 0.094 3.5 ± 2.1 0.2 ± 0.01 1.0 ± 0.6
11A17 wt wt wt I460V 3 0.5 0.125 0.125 0.4 ± 0.1 9.9 ± 2.4 79.7 ± 21.4
08L06 wt wt wt I460V 3 0.5 0.094 0.094 1.1 ± 0.2 0.3 ± 0.07 0.3 ± 0.1
01C06 wt wt K137N I460V 3 0.38 0.125 0.125 11.4 ± 4.7 1.3 ± 0.4 12.2 ± 4.4
99H10 wt wt wt wt 1.5 0.19 0.094 0.094 8.2 ± 2.1 0.5 ± 0.08 18.9± 3.1
04A24 wt wt wt I460V 8 1 0.19 0.125 5.6 ± 3.4 0.4 ± 0.1 15.5 ± 4.9
03N11 wt wt S79Y I460V 16 2 0.19 0.19 8.0 ± 3.3 1.4 ± 0.2 41.1 ± 8.7
10A19 wt wt wt I493L 4 0.5 0.125 0.094 0.6 ± 0.3 0.0 ± 0.00 73.2 ± 50.1
13F15 S114G wt wt wt 8 1 0.19 0.19 1.3 ± 0.3 1.1 ± 0.2 10.8 ± 2.6
99G11 wt wt wt I460V 6 0.75 0.125 0.125 9.7 ± 2.4 2.9 ± 0.6 19.5 ± 0.7
11A27 S114G wt N91D I493L 8 1 0.19 0.125 2.8 ± 1.7 3.1 ± 1.9 32.0 ± 17.3
09K15 wt wt wt I460V 4 0.5 0.094 0.094 1.2 ± 0.3 0.6 ± 0.2 0.7 ± 0.2
01C35 S114G wt S79Y/N91D I460V 16 2 0.125 0.125 16.3 ± 5.9 3.4 ± 1.1 0.15 ± 0.05
01G18 wt wt wt I460V 4 0.38 0.125 0.094 14.3 ± 3.8 3.5 ± 0.3 30.8 ± 4.9
03 K18 wt wt wt I460V 8 0.75 0.125 0.125 6.2 ± 5.4 13.5 ± 16.6 9.8 ± 11.4
03 L23 wt wt S79F D435K 32 2 0.19 0.19 7.9 ± 4.1 11.5 ± 5.8 153.9 ± 73.3
06H02 S114G wt wt wt >32 2 0.19 0.125 0.8 ± 0.3 2.0 ± 1.5 0.3 ± 0.1
13G08 S114G wt N91D wt 16 1 0.19 0.19 1.5 ± 0.6 5.4 ± 2.4 34.0 ± 15.8
03L28 wt wt K137N I460V >32 1.5 0.125 0.125 11.6 ± 3.3 1.7 ± 0.4 18.6 ± 4.6
99J16 wt wt wt I460V 8 0.38 0.094 0.094 6.5 ± 0.4 6.0 ± 1.3 56.5 ± 13.6
Open in a new tab

a Based on E-test.

Since putative highly different genetic backgrounds preclude reliable strain-to-strain comparison, we performed Kruskal-Wallis testing (with Dunn’s multiple comparison test) on three sample groups of strains either susceptible, intermediate or resistant to CIP (S1 Fig). This non-parametric method showed no statistically significant differences in pmrA expression among the three groups. In contrast, both patA and patB expression was significantly upregulated in CIP-resistant, but not in CIP-intermediate S. pneumoniae strains. Although this correlated with the observed susceptibility to reserpine, the levels of reserpine-mediated MIC reductions varied strongly among strains with similar transcript levels. For example, strains 99J16 and 13L23 both strongly overexpressed patA (6.0±1.3 and 14.8±4.4, resp.) and patB (56.5±13.6 and 48.4±10.5, resp.), but showed a sixteen- vs. threefold reduction in MICCIP in the presence of the efflux pump inhibitor.

Conversely, strain 10N11 also overexpressed patA and patB but showed no reserpine-dependent reduction of MICCIP (Table 3). Notably, in 12 and 19 isolates only patA or patB were overexpressed, respectively, arguing against uniform operon coregulation for these genes. Finally, in 17.0% of the reserpine-susceptible strains both patA and patB were downregulated. Since the heterogeneous PatAB pump requires both functional subunits to be functional [36], these two last observations strongly indicate the presence of other reserpine-sensitive systems involved in FQ-R.

Constitutive induction of patA has very recently been correlated to disruption of the transcriptional terminator of the upstream hexA gene [22,24]. We therefore sequenced this upstream region in 103 isolates. Although none of previous described mutations were retrieved, we identified six novel mutations: C(-41)T, G(-40)A, G(-46)T, G(-48)A, G(-49)A and C(-28)T. Each of these mutations could be related to decreased hairpin stability (ΔG increases > 3.2 kCal/mol), leading to increased transcription. The A(-52)G mutation was found not to play a role in patA regulation. It is important to note that these mutations were found in only a fraction (15.5%) of the isolates which overexpress patA, implying that terminator disruption is only a minor regulatory mechanism in the isolates under study.

Discussion

At the introduction of the respiratory fluoroquinolones LVX and MXF in the treatment of (a)typical pneumonia, there was concern that while treatment success in the short term could be enhanced, highly FQ-R S. pneumoniae strains would emerge by accumulation of additional QRDR mutations [37]. The continued high use of CIP for specific respiratory indications, such as the treatment of bronchial infections in cystic fibrosis patients [13], poses an additional risk factor to select for first-step ParC mutations which precede the ones in GyrA under CIP selective pressure. Moreover, the continuous exposure to sub-MIC levels of CIP and levofloxacin has been shown to select for efflux overexpression [38].

In our surveillance data on FQ-R among Belgian non-invasive S. pneumoniae isolates (1995–2014), some evidence points in this direction. From 2011 onwards, we observe a trend towards increased resistance to CIP and ofloxacin, and (although only visible at the MIC50 level) also for LVX. Our data from CST typing clearly indicates no clonal spread of CIP-R isolates, and thereby suggests there is no direct influence of vaccination campaigns on FQ-R in non-invasive pneumococci. The preference of first-step mutations in ParC is reflected by the 4:1 ratio of single QRDR mutations in the Topoisomerase IV subunits compared to the DNA Gyrase. Although a similar increase in CIP resistance was reported in Canada [10], this was not confirmed in other surveillance studies covering Europe, North America or Asia [8,9]. In contrast, resistance to MXF was only sporadic and globally minimal. As these trends are still very recent, it is critical that resistance rates and their changes are continuously monitored in the near future.

The exceptional case of high-level resistance to MXF (MICMXF+R of 32 μg/ml) was associated with a GyrB P454S mutation, combined with a mutated GyrA (S81L) subunit but a wild-type ParC/E. Notably, a Chinese group recently reported both ParE_P454S as GyrB_P454S to be associated with MXF resistance in combination with dually mutated GyrA and ParC residues [39,40]. However, our observation of a wild-type Topoisomerase IV QRDR region is important, as it contrasts with the current model which states that mutations in both topoisomerases are a prerequisite for high-level MXF resistance.

Analysis of the contribution of efflux pumps to pneumococcal FQ-R revealed no significant upregulation of the Major Facilitator PmrA in CIP resistant strains. We did observe varying constitutive expression of pmrA among clinical isolates, which has been shown before [16], but its contribution to drug resistance in non-invasive pneumococcal strains remains unclear. In contrast, non-parametric analyses showed marked higher expression of the ABC efflux pump PatAB associated with decreasing CIP susceptibility. Unfortunately, the underlying regulatory mechanism behind this upregulation remains unexplored. Although we found novel disruptive mutations in upstream transcriptional terminator sequences [22–24], this mechanism seems rather rare among clinical isolates as the large majority has wild-type upstream regions. A patA/B repressor has not been found or seems deleted in comparison to similar operons in related bacteria [41]. Various other levels of regulation can be envisioned at the post-transcriptional, translational or post-translational level.

Another important finding of this study is related to strains which seem deprived of known molecular FQ-R mechanisms, but yet display a resistant phenotype. For example, isolate 11I08 displays a wild-type QRDR yet a MICCIP+R of 24 μg/mL. A possibility is the involvement of chromosomally encoded qnr-like proteins, which shield topoisomerases from invading fluoroquinolones [42]. In contrast, many reserpine-susceptible strains did not express PatAB pumps, implying the involvement of other reserpine-sensitive efflux mechanisms in pneumococcus. This can be either novel efflux pumps, like the recently identified DinF transporter [43], or any of the five transporter genes found to be consistently induced by fluoroquinolones [44]. In any case, isolates with elevated MICs but without defined resistance mechanism are also commonly reported in other studies [3, 17, 25], and deserve more attention in the future.

We acknowledge limitations of the presented patAB expression studies. First of all, putative gene duplication of patA [23] could not be detected with the applied methods. Moreover, although we assessed constitutive gene expression, it has been shown that expression is quickly upregulated upon exposure to CIP, with patA being more strongly upregulated than patB [19,40]. This might level out the difference we observed in basal expression levels between both genes.

In conclusion, 15 years after the introduction of respiratory fluoroquinolones, we observe a concerning rise in resistance among non-invasive pneumococci. MXF remains a very potent drug with minimal level of resistance, but a combination of rare mutations in the DNA Gyrase was associated with full resistance to this compound. While target topoisomerase mutations and efflux pump (over)expression clearly contribute to FQ-R, we add novel isolates to the existing collection of strains deprived of known molecular mechanisms of fluoroquinolone resistance. It would be of great value to bring these clinical isolates together, and unravel their resistance mechanisms through a profound, comparative molecular characterization at the genomic, transcriptomic and proteomic level.

Supporting Information

S1 Fig. Gene expression analyses.

(DOCX)

Click here for additional data file. (39.4KB, docx)
S1 Table. MIC distribution of the reference strains used in the broth microdilution experiments.

(DOCX)

Click here for additional data file. (14.1KB, docx)
S2 Table. Oligonucleotides used in this study.

(DOCX)

Click here for additional data file. (27.1KB, docx)
S3 Table. Results of CST typing.

(DOCX)

Click here for additional data file. (29.1KB, docx)
S4 Table. QRDR sequencing and MIC determination of a selection of 422 pneumococcal strains.

(DOCX)

Click here for additional data file. (89.8KB, docx)

Acknowledgments

F.V.B. is maître de recherches of the Belgian Fonds de la Recherche Scientifique. V. Mohymont provided dedicated technical assistance. The Belgian Streptococcus pneumoniae Study Group is comprised of Glupczynski, Y., Garrino, M.-G., CHU. de Mont-Godinne, 5530 Yvoir (Gerald.glupcynski@uclouvain.be). Carpentier, M. Hôpital de la Citadelle, 4000 Liège (Michel.carpentier@chrcitadelle.be). Mulongo, B., O. Fagnart, O., Simon A. Laboratoire Cebiodi, 1000 Bruxelles (Anne.simon@uclouvain.be). Goffinet, J-S., Goffinet, P. Clinique St-Joseph, 6700 Arlon (Pierre.goffinet@vivalia.be). Govaerts, D. CHU André Vésale, 6110 Montigny-le-Tilleul (Danielle.govaerts@chu-charleroi.be).Lefèvre, Ph. Hôpital Princesse Paola, 6900 Marche-en-Famenne (ph.lefevre@skynet.be). Lontie, M., Van Meensel, B. Medisch Centrum Huisartsen, 3000 Leuven (Britt_vanmeersel@mchlvwo.be).Cartuyvels, R., Magerman, K. Jessaziekenhuis, 3500 Hasselt (reinoud.cartuyvels@jessazh.be).Meunier, F., Mukuku Sifa, C. Hôpital de Jolimont, Rue Ferrer 159–7100 Haine-St-Paul (Cathy.mukukusifa@jolimont.be). Philippart, I., Moonens, F. CHR Hôpital de Warquignies, 7300 Boussu (Francoise.moonens@epicura.be). Surmont, I., De Laere, E., Vervaeke, S. H.-Hartziekenhuis,8800 Roeselare (svervaeke@azdelta.be). Van De Vyvere, M., Camps, K. A.Z. Stuivenberg, 2060 Antwerpen (Martine.vandevyvere@zna.be). Van Landuyt, H., Gordts, B., Nulens, E. A.Z. St.-Jan, 8000 Brugge (Eric.nulens@azsintjan.be). Van Nimmen, L., Ide, L. A.Z. Jan Palfijn, 9000 Gent (Louis.ide@janpalfijngent.be). Frans, J., Van Noyen, R. Imeldaziekenhuis, 2820 Bonheiden (Johan.frans@imelda.be).

Data Availability

All relevant data are within the paper and its Supporting Information files.

Funding Statement

Dr. Vanhoof reports grants and non-financial support from Bayer Healthcare Belgium NV/SA, grants from GlaxoSmith Kline, Belgium, grants from Les Amis des Institutes Pasteur à Bruxelles, non-financial support from Sanofi Aventis, Belgium, during the conduct of the study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.Bridy-Pappas AE, Margolis MB, Center KJ, Isaacman DJ. Streptococcus pneumoniae: description of the pathogen, disease epidemiology, treatment, and prevention. Pharmacotherapy 2005; 25: 1193–1212. [DOI] [PubMed] [Google Scholar]
  • 2.Liñares J, Ardanuy C, Pallares R, Fenoll A. Changes in antimicrobial resistance, serotypes and genotypes in Streptococcus pneumoniae over a 30-year period. Clin Microbiol Infect. 2010; 16: 402–410. 10.1111/j.1469-0691.2010.03182.x [DOI] [PubMed] [Google Scholar]
  • 3.Adam HJ, Hoban DJ, Gin AS, Zhanel GG. Association between fluoroquinolone usage and a dramatic rise in ciprofloxacin-resistant Streptococcus pneumoniae in Canada, 1997–2006. Int J Antimicrob Agents 2009; 3: 82–85. [DOI] [PubMed] [Google Scholar]
  • 4.Zhanel GG, Ennis K, Vercaigne L, Walkty A, Gin AS, Embil J, et al. A critical review of the fluoroquinolones: focus on respiratory infections. Drugs 2002; 62: 13–59. [DOI] [PubMed] [Google Scholar]
  • 5.Hooper DC. Mode of action of fluoroquinolones. Drugs 1999; 58 Suppl 2: 6–10. [DOI] [PubMed] [Google Scholar]
  • 6.Janoir C, Zeller V, Kitzis MD, Moreau NJ, Gutmann L. High-level fluoroquinolone resistance in Streptococcus pneumoniae requires mutations in parC and gyrA. Antimicrob Agents Chemother. 1996; 40: 2760–4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Jorgensen JH, Weigel LM, Ferraro MJ, Swenson JM, Tenover FC. Activities of newer fluoroquinolones against Streptococcus pneumoniae clinical isolates including those with mutations in the gyrA, parC, and parE loci. Antimicrob Agents Chemother. 1999; 43: 329–34. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Jones ME, Sahm DF, Martin N, Scheuring S, Heisig P, Thornsberry C, et al. Prevalence of gyrA, gyrB, parC, and parE mutations in clinical isolates of Streptococcus pneumoniae with decreased susceptibilities to different fluoroquinolones and originating from Worldwide Surveillance Studies during the 1997–1998 respiratory season. Antimicrob Agents Chemother. 2000; 44: 462–466. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Patel SN, Melano R, McGeer A, Green K, Low DE. Characterization of the quinolone resistant determining regions in clinical isolates of pneumococci collected in Canada. Ann Clin Microbiol Antimicrob. 2010; 9:3 10.1186/1476-0711-9-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Li X, Zhao X, Drlica K. Selection of Streptococcus pneumoniae mutants having reduced susceptibility to moxifloxacin and levofloxacin. Antimicrob Agents Chemother. 2002; 46: 522–524. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Smith HJ, Walters M, Hisanaga T, Zhanel GG, Hoban DJ. Mutant prevention concentrations for single-step fluoroquinolone-resistant mutants of wild-type, efflux-positive, or ParC or GyrA mutation-containing Streptococcus pneumoniae isolates. Antimicrob Agents Chemother. 2004; 48: 3954–3958. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Maeda Y, Murayama M, Goldsmith CE, Coulter WA, Mason C, Millar BC, et al. Molecular characterization and phylogenetic analysis of quinolone resistance-determining regions (QRDRs) of gyrA, gyrB, parC and parE gene loci in viridans group streptococci isolated from adult patients with cystic fibrosis. J Antimicrob Chemother. 2011; 66: 476–486. 10.1093/jac/dkq485 [DOI] [PubMed] [Google Scholar]
  • 13.Jumbe NL, Louie A, Miller MH, Liu W, Deziel MR, Tam VH, et al. Quinolone efflux pumps play a central role in emergence of fluoroquinolone resistance in Streptococcus pneumoniae. Antimicrob Agents Chemother. 2006; 50: 310–317. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Gill MJ, Brenwald NP, Wise R. Identification of an efflux pump gene, pmrA, associated with fluoroquinolone resistance in Streptococcus pneumoniae. Antimicrob Agents Chemother. 1999; 43: 187–189. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Piddock LJ, Johnson MM, Simjee S, Pumbwe L. Expression of efflux pump gene pmrA in fluoroquinolone-resistant and -susceptible clinical isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother. 2002; 46: 808–812. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Garvey MI, Baylay AJ, Wong RL, Piddock LJ. Overexpression of patA and patB, which encode ABC transporters, is associated with fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother. 2011; 55: 190–196. 10.1128/AAC.00672-10 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Garvey MI, Piddock LJ. The efflux pump inhibitor reserpine selects multidrug-resistant Streptococcus pneumoniae strains that overexpress the ABC transporters PatA and PatB. Antimicrob Agents Chemother. 2008; 52: 1677–1685. 10.1128/AAC.01644-07 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.El Garch F, Lismond A, Piddock LJ, Courvalin P, Tulkens PM, Van Bambeke F. Fluoroquinolones induce the expression of patA and patB, which encode ABC efflux pumps in Streptococcus pneumoniae. J Antimicrob Chemother. 2010; 65: 2076–2082. 10.1093/jac/dkq287 [DOI] [PubMed] [Google Scholar]
  • 19.Avrain L, Garvey M, Mesaros N, Glupczynski Y, Mingeot-Leclercq MP, Piddock LJ, et al. Selection of quinolone resistance in Streptococcus pneumoniae exposed in vitro to subinhibitory drug concentrations. J Antimicrob Chemother. 2007; 60: 965–972. [DOI] [PubMed] [Google Scholar]
  • 20.Robertson GT, Doyle TB, Lynch AS. Use of an efflux-deficient streptococcus pneumoniae strain panel to identify ABC-class multidrug transporters involved in intrinsic resistance to antimicrobial agents. Antimicrob Agents Chemother. 2005; 49: 4781–4783. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Baylay AJ, Ivens A, Piddock LJ. A novel gene amplification causes upregulation of the PatAB ABC transporter and fluoroquinolone resistance in Streptococcus pneumoniae. Antimicrob Agents Chemother. 2015; 59: 3098–108. 10.1128/AAC.04858-14 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Baylay AJ, Piddock LJ. Clinically relevant fluoroquinolone resistance due to constitutive overexpression of the PatAB ABC transporter in Streptococcus pneumoniae is conferred by disruption of a transcriptional attenuator. J Antimicrob Chemother. 2015; 70: 670–679. 10.1093/jac/dku449 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Lupien A, Gingras H, Bergeron MG, Leprohon P, Ouellette M. Multiple mutations and increased RNA expression in tetracycline-resistant Streptococcus pneumoniae as determined by genome-wide DNA and mRNA sequencing. J Antimicrob Chemother. 2015; 70: 1946–1959. 10.1093/jac/dkv060 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Lupien A, Billal DS, Fani F, Soualhine H, Zhanel GG, Leprohon P, et al. Genomic characterization of ciprofloxacin resistance in a laboratory-derived mutant and a clinical isolate of Streptococcus pneumoniae. Antimicrob Agents Chemother. 2013; 57: 4911–4919. 10.1128/AAC.00418-13 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Said MA, Johnson HL, Nonyane BAS, Deloria-Knoll M, O'Brien KL, AGEDD Adult Pneumococcal Burden Study Team, et al. Estimating the burden of pneumococcal pneumonia among adults: a systematic review and meta-analysis of diagnostic techniques. PLoS ONE 2013; 8: e60273 10.1371/journal.pone.0060273 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Ubukata K, Asahi Y, Yamane A, Konno M. Combinational detection of autolysin and penicillin-binding protein 2B genes of Streptococcus pneumoniae by PCR. J Clin Microbiol. 1996; 34: 592–6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Elberse KE, van de Pol I, Witteveen S, van der Heide HG, Schot CS, van Dijk A, et al. Population structure of invasive Streptococcus pneumoniae in The Netherlands in the pre-vaccination era assessed by MLVA and capsular sequence typing. PLoS One. 2011; 6: e20390 10.1371/journal.pone.0020390 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Blondeau JM, Vaughan D, Laskowski R, Borsos S; Canadian Antimicrobial Study Group. Susceptibility of Canadian isolates of Haemophilus influenzae, Moraxella catarrhalis and Streptococcus pneumoniae to oral antimicrobial agents. Int J Antimicrob Agents. 2001; 17:457–64. [DOI] [PubMed] [Google Scholar]
  • 29.Firsov AA, Alferova IV, Smirnova MV, Lubenko IY, Portnoy YA, Zinner SH. Comparative pharmacodynamics of the new fluoroquinolone ABT492 and levofloxacin with Streptococcus pneumoniae in an in vitro dynamic model. Int J Antimicrob Agents. 2005; 25: 409–13. [DOI] [PubMed] [Google Scholar]
  • 30.Pfaffl MW. Quantification strategies in real-time PCR In: Bustin SA, editor. A-Z of quantitative PCR, La Jolla; 2004; p. 87–112. [Google Scholar]
  • 31.Dang TN, Srinivasan U, Britt Z, Marrs CF, Zhang L, Ki M, et al. Efflux-mediated resistance identified among norfloxacin resistant clinical strains of group B Streptococcus from South Korea. Epidemiol Health. 2014; 36: e2014022 10.4178/epih/e2014022 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Kaatz GW, Seo SM, O'Brien L, Wahiduzzaman M, Foster TJ. Evidence for the existence of a multidrug efflux transporter distinct from NorA in Staphylococcus aureus. Antimicrob Agents Chemother. 2000; 44: 1404–6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Johnson AP, Warner M, Livermore DM. Activity of linezolid against multi-resistant gram-positive bacteria from diverse hospitals in the United Kingdom. J Antimicrob Chemother. 2000; 45:225–30. [DOI] [PubMed] [Google Scholar]
  • 34.Tubau F, Fernández-Roblas R, Liñares J, Martín R, Soriano F. In vitro activity of linezolid and 11 other antimicrobials against 566 clinical isolates and comparison between NCCLS microdilution and Etest methods. J Antimicrob Chemother. 2001; 47:675–80. [DOI] [PubMed] [Google Scholar]
  • 35.Riedel S, Neoh KM, Eisinger SW, Dam LM, Tekle T, Carroll KC. Comparison of commercial antimicrobial susceptibility test methods for testing of Staphylococcus aureus and Enterococci against vancomycin, daptomycin, and linezolid. J Clin Microbiol. 2014; 52: 2216–22. 10.1128/JCM.00957-14 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Boncoeur E, Durmort C, Bernay B, Ebel C, Di Guilmi AM, Croizé J, et al. PatA and PatB form a functional heterodimeric ABC multidrug efflux transporter responsible for the resistance of Streptococcus pneumoniae to fluoroquinolones. Biochemistry 2012; 51: 7755–7765. 10.1021/bi300762p [DOI] [PubMed] [Google Scholar]
  • 37.Wang YC, Lipsitch M. Upgrading antibiotic use within a class: tradeoff between resistance and treatment success. Proc Natl Acad Sci U S A. 2006;103: 9655–9660. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Bowker KE, Garvey MI, Noel AR, Tomaselli SG, Macgowan AP. Comparative antibacterial effects of moxifloxacin and levofloxacin on Streptococcus pneumoniae strains with defined mechanisms of resistance: impact of bacterial inoculum. J Antimicrob Chemother. 2013; 68: 1130–8. 10.1093/jac/dks537 [DOI] [PubMed] [Google Scholar]
  • 39.Zhang G, Tian W, Wang C, Feng J. Identification of a novel resistance mutation in parE that confers high-level resistance to moxifloxacin in Streptococcus pneumoniae. J Antimicrob Chemother 2012; 67 (11): 2773–2774. 10.1093/jac/dks262 [DOI] [PubMed] [Google Scholar]
  • 40.Zhang G, Wang C, Sui Z, Feng J. Insights into the evolutionary trajectories of fluoroquinolone resistance in Streptococcus pneumoniae. J Antimicrob Chemother. 2015; 70: 2499–2506. 10.1093/jac/dkv134 [DOI] [PubMed] [Google Scholar]
  • 41.Guérin F, Galimand M, Tuambilangana F, Courvalin P, Cattoir V. Overexpression of the novel MATE fluoroquinolone efflux pump FepA in Listeria monocytogenes is driven by inactivation of its local repressor FepR. PLoS One 2014; 9: e106340 10.1371/journal.pone.0106340 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Jacoby GA, Hooper DC. Phylogenetic analysis of chromosomally determined qnr and related proteins. Antimicrob Agents Chemother. 2013; 57: 1930–1934. 10.1128/AAC.02080-12 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Tocci N, Iannelli F, Bidossi A, Ciusa ML, Decorosi F, Viti C, et al. Functional analysis of pneumococcal drug efflux pumps associates the MATE DinF transporter with quinolone susceptibility. Antimicrob Agents Chemother. 2013; 57: 248–253. 10.1128/AAC.01298-12 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Marrer E, Satoh AT, Johnson MM, Piddock LJ, Page MG. Global transcriptome analysis of the responses of a fluoroquinolone-resistant Streptococcus pneumoniae mutant and its parent to ciprofloxacin. Antimicrob Agents Chemother. 2006; 50: 269–278. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

S1 Fig. Gene expression analyses.

(DOCX)

Click here for additional data file. (39.4KB, docx)
S1 Table. MIC distribution of the reference strains used in the broth microdilution experiments.

(DOCX)

Click here for additional data file. (14.1KB, docx)
S2 Table. Oligonucleotides used in this study.

(DOCX)

Click here for additional data file. (27.1KB, docx)
S3 Table. Results of CST typing.

(DOCX)

Click here for additional data file. (29.1KB, docx)
S4 Table. QRDR sequencing and MIC determination of a selection of 422 pneumococcal strains.

(DOCX)

Click here for additional data file. (89.8KB, docx)

Data Availability Statement

All relevant data are within the paper and its Supporting Information files.

Articles from PLoS ONE are provided here courtesy of PLOS

RESOURCES